BioSpace News Archive

Ambu Inc., the world leader in single-use endoscopes, announced today that it has been awarded a contract in the category of Video Laryngoscopes with Vizient Inc.

Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports: Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans.

At the Radiological Society of North America’s 2021 Annual Meeting, GE Healthcare introduced its Revolution Apex platformiv – an industry firsti computed tomography (CT) platform with built-in scalability for onsite CT detector upgrades from 40 mm to 80 mm or 160 mm detector coverage – all without replacing the gantryii

CPhI awards the first ever CPhI Verified certificate to Medinfar – an international pharmaceutical manufacturer of Rx, cosmetics, food supplements and veterinary products.

AB Science SA (Euronext - FR0010557264 - AB) today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19.

Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 400 employers and millions of members, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a business update call with its chairman and CEO, Mike Martino, at 4:30 p.m. EST on Wednesday, Dec. 1, 2021.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the company will host a live investor and analyst webcast on Tuesday, November 30, 2021 reporting on data from the ongoing global Phase 2 TIDAL study evaluating zandelisib in patients with relapsed or refractory follicular lymphoma.

Outlook Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 46,000,000 shares of common stock of the Company at a price to the public of $1.25 per share, which includes the exercise in full of the underwriter’s option to purchase additional shares.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of D360 version 21.5, an industry-leading scientific informatics software for discovery scientists to integrate many data sources and analyze small molecules and biologic drugs for fast, high-confidence go/no-go decisions.